Cantor Fitzgerald Reiterates “Buy” Rating for Bausch Health Companies (BHC)

Cantor Fitzgerald reiterated their buy rating on shares of Bausch Health Companies (NYSE:BHC) in a research report released on Wednesday. The brokerage currently has a $32.00 price target on the stock.

“We rate BHC as 12-month price target of $32. A greater appreciation for BHC’s solid execution and future growth prospects under the new management team should drive upwards earnings revisions in 2019+, multiple expansion, and BHC shares higher. Valuation Summary We use a blend of DCF and multiples (EV/EBITDA) analysis to get to our 12-month price target of $32.”,” Cantor Fitzgerald’s analyst wrote.

Several other analysts have also recently issued reports on the stock. BMO Capital Markets upped their price objective on shares of Bausch Health Companies from $20.00 to $22.00 and gave the company a market perform rating in a research note on Monday, August 13th. Wells Fargo & Co reaffirmed a sell rating on shares of Bausch Health Companies in a research note on Monday, August 6th. Piper Jaffray Companies set a $13.00 price objective on shares of Bausch Health Companies and gave the company a sell rating in a research note on Monday, July 23rd. Royal Bank of Canada upped their price objective on shares of Bausch Health Companies from $25.00 to $26.00 and gave the company a hold rating in a research note on Wednesday, August 8th. Finally, Mizuho reaffirmed a buy rating and set a $31.00 price objective on shares of Bausch Health Companies in a research note on Tuesday, August 7th. Three analysts have rated the stock with a sell rating, four have given a hold rating and three have issued a buy rating to the stock. Bausch Health Companies has a consensus rating of Hold and a consensus price target of $25.38.

Shares of NYSE BHC opened at $22.35 on Wednesday. Bausch Health Companies has a 12-month low of $10.94 and a 12-month high of $27.79. The stock has a market cap of $8.21 billion, a P/E ratio of 6.13, a price-to-earnings-growth ratio of 0.34 and a beta of -0.43. The company has a debt-to-equity ratio of 6.99, a current ratio of 1.14 and a quick ratio of 0.89.

Bausch Health Companies (NYSE:BHC) last announced its quarterly earnings data on Tuesday, August 7th. The company reported $0.93 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.81 by $0.12. Bausch Health Companies had a negative net margin of 20.60% and a positive return on equity of 27.83%. The company had revenue of $2.13 billion during the quarter, compared to analysts’ expectations of $2.05 billion. equities analysts forecast that Bausch Health Companies will post 3.47 earnings per share for the current year.

A number of large investors have recently bought and sold shares of the business. Private Management Group Inc. acquired a new position in Bausch Health Companies in the 2nd quarter valued at about $28,474,000. Tobam acquired a new position in Bausch Health Companies in the 2nd quarter valued at about $13,886,000. Van ECK Associates Corp acquired a new position in Bausch Health Companies in the 2nd quarter valued at about $11,494,000. Marshall Wace LLP acquired a new position in Bausch Health Companies in the 2nd quarter valued at about $2,974,000. Finally, Point View Wealth Management Inc. acquired a new position in Bausch Health Companies in the 2nd quarter valued at about $1,132,000. Institutional investors own 44.66% of the company’s stock.

Bausch Health Companies Company Profile

Bausch Health Companies Inc develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. It offers dermatology products that treat a range of conditions, including actinic keratosis, acne, atopic dermatitis, psoriasis, cold sores, athlete's foot, nail fungus, and other dermatoses, as well as provides aesthetic medical devices, which address various conditions, including facial wrinkles, acne, pigmentation conditions, body sculpting, skin tightening, and laser hair removal.

Recommended Story: Average Daily Trade Volume – What It Means In Stock Trading

Analyst Recommendations for Bausch Health Companies (NYSE:BHC)

Receive News & Ratings for Bausch Health Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch Health Companies and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply